Zacks Investment Research upgraded shares of Constellation Pharmaceuticals (NASDAQ:CNST) from a hold rating to a buy rating in a research report released on Tuesday, Zacks.com reports. The firm currently has $11.00 target price on the stock.
According to Zacks, “Constellation Pharmaceuticals, Inc. operates as a bio-pharmaceutical company. It discovers and develops molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. The company’s lead product candidates consists of CPI-1205, which inhibits enhancer of zeste homolog 2 and CPI-0610, which inhibits bromodomain and extra terminal domain. Constellation Pharmaceuticals, Inc. is based in Cambridge, United States. “
Other equities research analysts have also recently issued reports about the company. Oppenheimer increased their price target on Constellation Pharmaceuticals from $14.00 to $18.00 and gave the company an outperform rating in a research note on Tuesday, April 2nd. HC Wainwright reiterated a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Constellation Pharmaceuticals has an average rating of Buy and an average target price of $17.29.
Constellation Pharmaceuticals (NASDAQ:CNST) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05. Analysts predict that Constellation Pharmaceuticals will post -3.13 EPS for the current year.
Several hedge funds have recently made changes to their positions in CNST. Northern Trust Corp grew its holdings in Constellation Pharmaceuticals by 12.4% during the fourth quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock worth $204,000 after acquiring an additional 5,624 shares during the period. Geode Capital Management LLC grew its holdings in Constellation Pharmaceuticals by 16.9% during the fourth quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock worth $55,000 after acquiring an additional 1,987 shares during the period. Casdin Capital LLC grew its holdings in Constellation Pharmaceuticals by 18.4% during the fourth quarter. Casdin Capital LLC now owns 1,556,998 shares of the company’s stock worth $6,244,000 after acquiring an additional 242,255 shares during the period. Sphera Funds Management LTD. acquired a new stake in Constellation Pharmaceuticals during the fourth quarter worth about $281,000. Finally, BNP Paribas Arbitrage SA grew its holdings in Constellation Pharmaceuticals by 4,092.4% during the first quarter. BNP Paribas Arbitrage SA now owns 3,312 shares of the company’s stock worth $45,000 after acquiring an additional 3,233 shares during the period. 64.38% of the stock is currently owned by institutional investors and hedge funds.
Constellation Pharmaceuticals Company Profile
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
See Also: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.